AstraZeneca (AZN) Stock: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$171.49
-1.08 (-0.63%)
▼
5d:
+3.68%
30d:
+4.21%
90d:
+1.09%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 30, 2026
4d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AZN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AZN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$409.25
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$254.11
32.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $171.49, which is considered extended relative to its 30-day fair value range of $159.07 to $167.92. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.1) compared to its historical average (24.1). Remarkably, the market is currently pricing in an annual earnings decline of 14.4% over the next few years. This pessimistic expectation contrasts with the company's recent 2.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $173.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AZN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $206.66 (+20.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $173.91. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AZN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $206.66 (+20.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$159.07 -
$167.92
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.5% below Wall St target ($206.66)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$159.07 -
$167.92
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$154.00
Resistance Level
$173.91
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.12
Wall Street Target
$206.66
(+20.5%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
2.5%
Profit Margin
17.0%
Valuation Discount vs History
-14.4% cheaper
PE vs Historical
15.1 vs 24.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.4%
(market-implied from PE analysis)
1-Year Target
$154.34
(-10%)
2-Year Target
$138.91
(-19%)
3-Year Target
$125.02
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→24)
$199.29
(+16%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 12.9%)
$323.92
(+89%)
Base:
(SPY PE: 15.1, Growth: 12.9%)
$246.58
(+44%)
Bear:
(PE: 12.9, Growth: 12.9%)
$209.59
(+22%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 25.80 | Current EPS (TTM): $6.69
Bull Case
$321.86
(+88%)
Analyst growth 69.6%, PE expands to 28.4
Base Case
$292.60
(+71%)
Market implied 69.6%, PE stable at 25.8
Bear Case
$117.35
(-32%)
Severe decline -20.0%, PE contracts to 21.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.1 to 24.1
Stabilization Target:
$273.37
(+59.4%)
PE Expansion Potential:
+59.4%
Share & Embed Analysis
Last updated: October 24, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$283 | 45 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1328 | 33 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 41 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$244 | 43 HOLD |
